{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:50:25Z","timestamp":1794469825459,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82230004"],"award-info":[{"award-number":["No. 82230004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82430006"],"award-info":[{"award-number":["No. 82430006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82400157"],"award-info":[{"award-number":["No. 82400157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7242154"],"award-info":[{"award-number":["No. 7242154"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7232188"],"award-info":[{"award-number":["No. 7232188"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75344-7","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:04:45Z","timestamp":1784999085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Peng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Xia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-2492","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Shuang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-0216","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-9560","authenticated-orcid":false,"given":"Li-Ping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Sha","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"75344_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero, F. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113, 2386\u20132393 (2009).","journal-title":"Blood"},{"key":"75344_CR2","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert, C. et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117, 4190\u2013207 (2011).","journal-title":"Blood"},{"key":"75344_CR3","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert, C. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3, 3829\u201366 (2019).","journal-title":"Blood Adv."},{"key":"75344_CR4","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan, D. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 3, 3780\u2013817 (2019).","journal-title":"Blood Adv."},{"key":"75344_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/ajh.24463","volume":"91","author":"F Efficace","year":"2016","unstructured":"Efficace, F. et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am. J. Hematol. 91, 995\u20131001 (2016).","journal-title":"Am. J. Hematol."},{"key":"75344_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","volume":"381","author":"N Cooper","year":"2019","unstructured":"Cooper, N. & Ghanima, W. Immune thrombocytopenia. N. Engl. J. Med. 381, 945\u201355 (2019).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.2019003599","volume":"135","author":"O Miltiadous","year":"2020","unstructured":"Miltiadous, O., Hou, M. & Bussel, J. B. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 135, 472\u2013490 (2020).","journal-title":"Blood"},{"key":"75344_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel, J. et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am. J. Hematol. 93, 921\u2013930 (2018).","journal-title":"Am. J. Hematol."},{"key":"75344_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","volume":"386","author":"DJ Kuter","year":"2022","unstructured":"Kuter, D. J. et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N. Engl. J. Med. 386, 1421\u20131431 (2022).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","volume":"402","author":"CM Broome","year":"2023","unstructured":"Broome, C. M. et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 402, 1648\u20131659 (2023).","journal-title":"Lancet"},{"key":"75344_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/ajh.26045","volume":"96","author":"N Cooper","year":"2021","unstructured":"Cooper, N. et al. Immune Thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am. J. Hematol. 96, 188\u2013198 (2021).","journal-title":"Am. J. Hematol."},{"key":"75344_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash, P. et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann. Rheum. Dis. 80, 71\u201387 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"75344_CR13","unstructured":"Evaluation, C. f. D. & Research. Clinical Pharmacology and Biopharmaceutics Review: Baricitinib (U.S. Food and Drug Administration, 2017)."},{"key":"75344_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","volume":"81","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner, T. et al. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1267\u20131272 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"75344_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243\u201352 (2016).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor, P. C. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 376, 652\u201362 (2017).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace, D. J. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392, 222\u201331 (2018).","journal-title":"Lancet"},{"key":"75344_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001\u20131010 (2023).","journal-title":"Lancet"},{"key":"75344_CR19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King, B. et al. Two phase 3 trials of baricitinib for alopecia areata. N. Engl. J. Med. 386, 1687\u201399 (2022).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR20","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1002\/ajh.27433","volume":"99","author":"P Zhao","year":"2024","unstructured":"Zhao, P. et al. Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: an open-label pilot study. Am. J. Hematol. 99, 1951\u20131958 (2024).","journal-title":"Am. J. Hematol."},{"key":"75344_CR21","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/S2352-3026(17)30170-9","volume":"4","author":"FE Feng","year":"2017","unstructured":"Feng, F. E. et al. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 4, e487\u2013e496 (2017).","journal-title":"Lancet Haematol."},{"key":"75344_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","volume":"96","author":"S Wang","year":"2012","unstructured":"Wang, S. et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int. J. Hematol. 96, 222\u2013228 (2012).","journal-title":"Int. J. Hematol."},{"key":"75344_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1076029615622002","volume":"22","author":"W Liu","year":"2016","unstructured":"Liu, W. et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin. Appl. Thromb. Hemost. 22, 727\u2013733 (2016).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"75344_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1185\/03007990802634119","volume":"25","author":"SD Mathias","year":"2009","unstructured":"Mathias, S. D. et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr. Med. Res. Opin. 25, 375\u201383 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"75344_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","volume":"45","author":"EC Keystone","year":"2018","unstructured":"Keystone, E. C. et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J. Rheumatol. 45, 14\u201321 (2018).","journal-title":"J. Rheumatol."},{"key":"75344_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen, S. C. J. et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 40, 843\u201356 (2020).","journal-title":"Pharmacotherapy"},{"key":"75344_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426\u2013435 (2015).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser, R. et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N. Engl. J. Med. 385, 228\u2013238 (2021).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"75344_CR30","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa, R. A. et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 4, e225\u201336 (2017).","journal-title":"Lancet Haematol."},{"key":"75344_CR31","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison, C. N. et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 4, e317\u201324 (2017).","journal-title":"Lancet Haematol."},{"key":"75344_CR32","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2014-03-559815","volume":"124","author":"R Besancenot","year":"2014","unstructured":"Besancenot, R. et al. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood 124, 2104\u20132115 (2014).","journal-title":"Blood"},{"key":"75344_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3324\/haematol.2011.046417","volume":"96","author":"AM Rocha","year":"2011","unstructured":"Rocha, A. M. et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 96, 1560\u20131564 (2011).","journal-title":"Haematologica"},{"key":"75344_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller, A. B. et al. Reporting results of cancer treatment. Cancer 47, 207\u201314 (1981).","journal-title":"Cancer"},{"key":"75344_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.clinthera.2007.05.005","volume":"29","author":"SD Mathias","year":"2007","unstructured":"Mathias, S. D. et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin. Ther. 29, 950\u201362 (2007).","journal-title":"Clin. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75344-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:58:17Z","timestamp":1787785097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75344-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75344"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75344-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9102"}}